Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington’s Disease
Authors:
- 11 July 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (14) , 9819-9845
Abstract
The Rho kinase (ROCK) pathway is implicated in the pathogenesis of several conditions, including neurological diseases. In Huntington's disease (HD), ROCK is implicated in mutant huntingtin (HTT) aggregation and neurotoxicity, and members of the ROCK pathway are increased in HD mouse models and patients. To validate this mode of action as a potential treatment for HD, we sought a potent, selective, central nervous system (CNS)-penetrant ROCK inhibitor. Identifying a compound that could be dosed orally in mice with selectivity against other AGC kinases, including protein kinase G (PKG), whose inhibition could potentially activate the ROCK pathway, was paramount for the program. We describe the optimization of published ligands to identify a novel series of ROCK inhibitors based on a piperazine core. Morphing of the early series developed in-house by scaffold hopping enabled the identification of a compound exhibiting high potency and desired selectivity and demonstrating a robust pharmacodynamic (PD) effect by the inhibition of ROCK-mediated substrate (MYPT1) phosphorylation after oral dosing.Keywords
This publication has 26 references indexed in Scilit:
- Direct Binding and Regulation of RhoA Protein by Cyclic GMP-dependent Protein Kinase IαJournal of Biological Chemistry, 2012
- Rho Kinase As a Therapeutic Target in Cardiovascular DiseaseFuture Cardiology, 2011
- In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native KinasesChemistry & Biology, 2011
- Rho kinase and hypertensionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical SuccessJournal of Medicinal Chemistry, 2009
- Discovery of Substituted 4-(Pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as Potent and Highly Selective Rho Kinase (ROCK-II) InhibitorsJournal of Medicinal Chemistry, 2008
- Phosphorylation of Profilin by ROCK1 Regulates Polyglutamine AggregationMolecular and Cellular Biology, 2008
- Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase InhibitorsJournal of Medicinal Chemistry, 2006
- Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivoHuman Molecular Genetics, 2005